The Neo Comprehensive - Myeloid Disorders assay detects relevant aberrations for the purpose of diagnostic evaluation, prognosis, risk stratification, and therapy guidance. It covers a wide spectrum of myeloid neoplasms, including acute myeloid leukemia (AML); chronic myeloid leukemia (CML); chronic myelomonocytic leukemia (CMML); myelodysplastic neoplasms (MDS); myeloproliferative neoplasms (MPN), e.g., polycythemia vera (PV), primary myelofibrosis (PMF), and essential thrombocythemia (ET); myeloid neoplasms with eosinophilia and defining gene rearrangement; histiocytic neoplasms, such as Langerhans cell histiocytosis (LCH) or Erdheim-Chester Disease (ECD); mastocytosis; myeloid precursor lesions.
Acute Myelogenous Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
ABL1 (ABL proto-oncogene 1), ANKRD26 (Ankyrin Repeat Domain Containing 26), APC (APC Regulator Of WNT Signaling Pathway), ARAF (A-Raf Proto-Oncogene), ASXL1 (ASXL Transcriptional Regulator 1), ATM (ATM serine/threonine kinase)
See More ...
Next-Generation Sequencing (NGS)